Group of students with mask on their faces
Thierry Bernard, Chief Executive Officer and Managing Director

With focus on the COVID-19 pandemic, the world has taken its eye off TB

Tuberculosis is highly infectious and a global problem that COVID-19 has only made worse. Two legacies of the response to COVID-19 give rise to hope. Thierry Bernard, CEO of QIAGEN, says many health systems now have unprecedented testing and tracing capacity that can be used to test for TB.
About 10 million people contract and over one million die from tuberculosis every year, most in countries far away from the wealthy West. But yesterday’s World Tuberculosis Day serves as a reminder that this very curable disease is a global problem – one that’s getting worse. The COVID-19 pandemic shows communicable diseases respect no borders, and TB remains a stubborn feature of Western cities, not just developing nations. With 150 cases per 100,000 people, parts of London in the recent past had higher TB rates than Iraq or Rwanda. Areas of New York City such as Sunset Park or West Queens in 2019 had rates six times the national average, and French experts last year have worried again about “hotspots” in northern Paris.

Three things compound this problem. Before becoming active and infectious, usually attacking the lungs, TB can lie dormant for years. Experts estimate that about one in four people alive today – roughly two billion – carry latent TB and around 10 percent of them will develop active TB over a lifetime. That means the 10 million people who develop active TB every year represent only the tip of the iceberg. The world has many people enduring active TB – and is teeming with latent TB cases constantly morphing into infectious ones.
Doctor, female, xray
The 10 million people who develop active TB every year represent only the tip of the iceberg. The world has many people enduring active TB – and is teeming with latent TB cases constantly morphing into infectious ones.
Thierry Bernard, Chief Executive Officer and Managing Director

TB is on the rise again

The second problem is that COVID-19 forced us to take our eye off the ball. As the world has concentrated on testing for and tracing the SARS-CoV-2 pathogen, testing for and tracing TB plummeted. Deaths from this bacterial disease had fallen from 1.7 million in 2000 to 1.2 million in 2019. But our recent inattention means TB numbers are expected to rise again. The Stop TB partnership of governmental and non-governmental groups reckons we could easily face an extra 1.4 million deaths and 6.3 million active cases over the next five years. It’s safe to assume that the number of additional, new latent TB cases is many multiples higher.

Thirdly, we have to contend with this enlarged reservoir of latent TB just as the world limbers up again after various waves of COVID-19-induced lockdown. People all over the world will travel again and they will congregate to study, do business or enjoy just being together again. As the world begins to teem again, millions of people will develop active TB after months or years of carrying the latent disease undetected in their bodies. Their symptoms may be mild and go undiagnosed and untreated for months. The World Health Organization (WHO) reckons such sufferers can infect 10–15 other people over a year.
special app viewing on phone

We have to contend with this enlarged reservoir of latent TB just as the world limbers up again after various waves of COVID-19-induced lockdown. People all over the world will travel again and they will congregate to study, do business or enjoy just being together again.

Thierry Bernard, Chief Executive Officer and Managing Director

More screening for latent TB

The confluence of these factors means the 1500 organizations of the Stop TB partnership fear that the fight against TB could be set back by five to eight years. The governments in the WHO want to cut annual TB deaths by 90 percent from 2015 levels and annual new cases by 80 percent by 2035 – by screening for latent TB and preventing cases from becoming active, by testing for and treating active cases and tracing contacts. If Stop TB’s warnings prove correct, its resolute actions over recent years will have been undone.

Luckily, the sterling work of the WHO, Stop TB and their partners, which work under the umbrella of the United Nations, means this worst case is not a foregone conclusion. The world can redouble its anti-TB measures to identify and treat people with TB and quickly shrink the recently enlarged pool of undiagnosed cases. That would require a resounding return to screening for and treating latent cases, as well as ramped-up testing for active cases alongside community engagement and contact tracing. That means we have to make sure that as many latent and active TB sufferers as possible get access to the right treatment as quickly as possible.
 Refugee family
Millions of people will develop active TB after months or years of carrying the latent disease undetected in their bodies. Their symptoms may be mild and go undiagnosed and untreated for months. The World Health Organization (WHO) reckons such sufferers can infect 10–15 other people over a year.
Thierry Bernard, Chief Executive Officer and Managing Director

Make use of the testing mindset

Ironically, there are two legacies of our response to COVID-19 that should give us hope for TB. Many health systems now have unprecedentedly large testing and tracing infrastructures that we can use to test for TB. Equally, ordinary people the world over have in the past year come to understand, support and even undergo tests for disease. This “testing mindset” allows governments to create unprecedented momentum for screening campaigns against latent TB. TB is one of the oldest infectious diseases whose traces have been found in ancient Egyptian pharaohs’ mummies. It has been haunting mankind for millennia. We still have a chance to finally get it under control.
portrait of Thierry Bernard
Thierry Bernard, Chief Executive Officer and Managing Director
Thierry Bernard joined QIAGEN in February 2015 to lead the company’s growing presence in molecular diagnostics, the application of Sample to Insight solutions for molecular testing in human healthcare. He was named Chief Executive Officer in March 2020 after serving in this role on an interim basis and became a member of the Managing Board in 2021. Previously, Mr. Bernard held roles of increasing responsibility during 15 years with bioMérieux SA, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region, and held senior management roles in several other leading international companies. He was named in March 2023 as Chair of the AdvaMedDx Board of Directors, a U.S. industry trade association. Mr. Bernard has earned degrees and certifications from Sciences Po, LSE, the College of Europe, Harvard Business School, Centro de Comercio Exterior de Barcelona, and has been appointed Conseiller du Commerce Extérieur by the French government.